Inogen Q4 revenue rises

Inogen

24/02/2026 21:39

Overview

Medical technology firm's Q4 revenue grew 2% yr/yr, driven by international sales

Company authorized $30 mln share repurchase program

Outlook

Inogen expects Q1 2026 revenue to match Q1 2025

Company forecasts 2026 revenue between $366 mln and $373 mln

Result Drivers

INTERNATIONAL SALES - Growth in international portable oxygen concentrator sales drove revenue increase, offsetting declines in U.S. sales and rentals

COST REDUCTIONS - Material cost reductions and operational efficiencies improved operating loss and profitability

Company press release: ID:nBw66J3Fra

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Adjusted Net Income
Beat
-$4 mln
-$9.70 mln (2 Analysts)
Q4 Net Income
-$7.1 mln
Q4 Adjusted EBITDA
Beat
-$1.70 mln
-$3.20 mln (2 Analysts)
Q4 Gross Margin
43.1%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Inogen Inc is $13.00, about 128.9% above its February 23 closing price of $5.68

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)